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Electrophoretic mobility shift assays were performed using oligonucleotides corresponding to known protein binding sites within the human insulin 
gene enhancer and nuclear extracts from mouse pancreatic a and /I cell lines. The results demonstrate that a previously described factor, IUF-1, 
binds to three sites at -82 (the CT1 box), -215 (the CT2 box), and -319 (the CT3 box) in the human insulin gene enhancer. ILJF-1 was present 
only ing but not in a cells, while all other DNA-binding proteins were present in both cell lines. IUF-1 may therefore be an important determinant 
of insulin gene /I cell-specific expression. 
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The insulin gene is expressed exclusively in the /I cells 
of the islets of Langerhans in adults. The &acting 
sequences involved in conferring tissue-specific expres- 
sion of the insulin gene are located within a region up 
to 350 base pairs from the transcription start site. 
Within this region two classes of &-acting element have 
been shown to play important roles in controlling ex- 
pression of the gene, E boxes and TAAT boxes [I]. In 
general E boxes, i.e. the consensus equence CANNTG, 
bind protein factors that contain he~x-loo~hel~ 
(HLI-I) dimerization domains [2]. In the rat insulin I 
gene an important regulatory factor, IEF-1 [3], a heter- 
odimer of the E2A gene product (E12/E47) [4-6] and a 
25 kDa protein, IESF-1 [7], has been shown to bind to 
two transcriptionally important E boxes at -103 and 
-233, the IEBl or NIR and IEB2 or FAR boxes, re- 
spectively [8,9]. IEF-1 is present in islet a and@ cells as 
well as a number of other endocrine cells, but is absent 
from non-endocrine cells [ IO,1 11. A promoter-proximal 
TAAT box is located at -86 [lo], while three TAAT 
boxes are located within an AT-rich region (The FLAT 
element) adjacent to the IEB21FAR box [12]. The pro- 
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moter-proximal TAAT box binds a /I cell factor, IPF-1 
[lo], while the FLAT element binds several factors in- 
cluding the homeodomain factors lmx-1, cdx3, isl-1 
and HNFla [13-151, and an uncharacterised factor 
called IEF-2 [lo]. The FAR and FLAT elements act 
synergistically as a mini-enhancer [131. 
In the human insulin gene the promoter-proximal E 
box (IEBl/NIR) is conserved, and binds a factor with 
similar properties to IEF-1 [16]. The distal E box (IEB2/ 
FAR) is not conserved in the human insulin gene, how- 
ever this region is transc~ptionally important [ 17j and 
has been identified as a binding site for the ubiquitous 
HLH protein USE; [16]. The human insulin gene con- 
tains TAAT box elements at -82 {the CT-1 box), -215 
(the CT-2 box) and at -319 (the CT-3 box). The CT-2 
box binds a factor called IUF- 1 [ 181. The human insulin 
gene also contains a powerful negative regulatory ele- 
ment (NRE) at -270, and several other protein binding 
sites including the GGl/GG2 motifs at - 145 to -130, 
a CAMP response element (CRE) at -183 to -176, an 
SPl site at -346 to -341, and an enhancer core se- 
quence at -314 to -306 [17]. 
The mouse pancreatic cell lines, aTCI and flC3, 
were derived from transgenic mice expressing the SV40 
large T antigen under the control of either the glucagon 
or insulin enhancer/promoter, espectively [19,20]. Tis- 
sue-specific expression of the transgene led to the for- 
mation of either glucagonomas or insulinomas, from 
which immortalised cell lines were established. aTC1 
and /ITC3 cells produce greater quantities of glucagon 
or of insulin than other islet cell lines. In addition, they 
may be closer to terminally differentiated cells than 
other islet cell lines, such as HIT T15 and RIN m5F 
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cells which produce comparatively low amounts of insu- 
lin, and are heterogeneous in phenotype, to some extent 
expressing the genes for glucagon and somatostatin as 
well as the insulin gene [21,22]. For this reason aTC1 
and ,8TC3 cells provide an interesting system for the 
study of tissue-specific islet hormone gene expression. 
The aim of the present study was to investigate the 
presence of human insulin gene enhancer-binding pro- 
teins in nuclear extracts from these two cell lines. 
2. EXPERIME~AL 
2.1. CeN lines 
Mouse pancreatic aTCl and /lTC3 cell lines were obtained from S. 
Efrat, Department of Molecular Pharmacology, Albert Einstein Col- 
lege of Medicine, Bronx, NY. 
2.2. Cell transfections and chloramphenicol acetyl transferase (CAT) 
assays 
The plasmid constructs pBCins-339 and pBCins-258 contain frag- 
ments of the human insulin gene from -339 to +112 or -258 to +112 
cloned into the expression vector pBC0 1231. Cells were transfected 
with 15 lug of reporter DNA and 6 pg of RSV;B galactosidase DNA 
by the calcium phosphate co-pr~ipitation method [24]. CAT assays 
were performed after no~alization to /l galactosidase activity as 
described by Gorman et al. [25]. 
2.3. Oligonucleotides 
Oligonucleotides were purchased from Alta Bioscience, University 
of Birmingham. Single stranded complementary oligonucleotides were 
annealed as previously described [26]. The following oligonucleotides 
corresponding to the indicated sequences in the human insulin gene 
were used: oligonucleotide J, which contains the human IEBl site 
(underlined) (-122 to -93, S-CTCAGCCCCCAGCCATCTGCC- 
GACCCCCCC-3’); oligonucleotide D, which contains the human 
IEB2 site (-248 to -219, S-ACAGGTCTGGCCACCGGGCCCC- 
TGGTTAAG-3’); oligonucleotide P, which contains the CT1 box 
(-92 to -68, S-CCCA~C~~T~~A~-3~; oligonucle- 
otide B, which contains the CT2 box (-230 to -201, 5’-CCCCTG- 
GTTAAGACTCTAATGACCCGCTGG-3’); oligonucleotide Bm2, 
which contains an A to C transversion within the CT2 box of oligo- 
nucleotide B (-230 to -201, S- CCCCTGGTTAAGACTCTACTG- 
ACCCGCTGG-3’); and oligonucleotide H, which contains the CT3 
box (-326 to -290, 5’-TCCTGGTCTAATGTGGAAAGTGGCCC- 
AGGTGAGGGC-3’). Oligonucleotide PI contained sequences -85 to 
-64 of the rat insulin I gene (S-GCCCTTAATGGGCCAAACG- 
GCA-33, while oligonucleotide Plm2 contained the change AA to CC 
(underlined) within oligonucleotide Pl (5’-GCCCTTWGGGCCA- 
AACGGCA3’). 
2.4. Eiectrophoretic ability shift assays 
Preparation of nuclear extracts and electrophoretic mobility shift 
assays were performed as previously described [26,2fi. 
3. RESULTS AND DISCUSSION 
aTC1 and flC3 cells were transfected with the con- 
structs pBCins-339 and pBCins-258 containing frag- 
ments from the region upstream of the human insulin 
gene, and with pRSVCAT as a positive control. Al- 
though the positive control gave high activity in both 
cell lines, the insulin promoter constructs were approx- 
imately ten-fold more active in DC3 than in aTC1 cells 
when normalised against pRSVCAT (Table I). Con- 
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Fig. 1. Binding of dTC1 and @TC3 nuclear proteins to oligonucleo- 
tides D and J. Electrophoretic mobility shift assay using oligonucleo- 
tides D or J as probes and aTC1 (A) and DC3 (B) nuclear extracts. 
The position of the major complexes, Jl and IX, are indicated. 
struct pBCins-258 was approximately 3-fold more ac- 
tive than construct pBCins-339 in both ceil lines, indi- 
cating that a negative regulatory element (NRE) located 
between -258 and -279 was active in cc and /3 cells. 
These results demonstrate that aTC1 and j?TC3 cells 
differ substantially in their ability to support insulin 
gene transcription. The following experiments were per- 
formed to determine to what extent this difference 
would be reflected in the pattern of expression of insulin 
enhancer-binding proteins between the two cell lines. 
The distribution of factors binding to the proximal E 
box (~EBl~IR) and the imperfect distal E box at -233 
Table I 
Transfection of DC3 and aTC1 cells with pRSVCAT, pBCins-258 
and pBCins-339 
Cell line pRSVCAT pBCins-258 pBCins-339 
BTC3 100 14.6 + 6.4 (4) 4.4 + 0.4 (4) 
aTC 1 100 1.4 + 0.6 (4) 0.54 -I 0.1 (4) 
For each cell line, recovered CAT activities were expressed relative to 
pRSVCAT. The values are the means of four independent determina- 
tions. 
Volume 329, number 1,2 
Probe 
Competitor - BBm2H P - 
FEBSLETTERS August 1993 
H P 
- BBm2H P - - BBm2H P - 
c’ 
Cell line B A -B A -B A 
Fig. 2. Binding of uTC1 and /3TC3 nuclear proteins to oligonucleotides B, H and P. Electrophoretic mobility shift assay using oligonucleotides 
B, H or P as probes and aTC1 (A) andflC3 (B) nuclear extracts. The indicated unlabelled competitor oligonucleotides were used in approximately 
50-fold excess. The position of the IUF-1 complex is indicated. 
was investigated using oligonucleotides J and D (Fig. 1). 
A factor, previously identified [16] as the HLH hetero- 
dimer IEF- 1 (Fig. 1, Jl), was detected in both aTC1 and 
/?TC3 cells using oligonucleotide J as probe. Using ol- 
igonucleotide D as a probe, a factor, previously identi- 
fied [16] as the HLH protein USF (Fig. 1, Dl) was also 
present in both cell lines. 
To investigate the binding specificity and distribution 
of factors binding to the three TAAT box sequences in 
the human insulin gene, three oligonucleotides (H, -325 
to -190; B, -230 to -201; and P,-92 to -68) were used. 
A single prominent complex with identical electro- 
phoretic mobility (Fig. 2) was observed using all three 
oligonucleotide probes. Self-competition and cross- 
competition for formation of this complex was observed 
with oligonucleotides B, H and P, but not with oligonu- 
cleotide Bm2, which contains an A- to C- transversion 
within the TAAT box element of oligonucleotide B. 
These results are consistent with the conclusion that the 
factor IUF-1 binds to the CT element [T/C]CTAATG 
within oligonucleotides B, H, and P. IUF-1 was present 
in the /ITC3 extract, but was absent from the clTC1 
extract (Fig. 2, tracks A). A faster mobility complex 
(B2) was observed with oligonucleotide B, however this 
complex was not abolished by excess unlabelled ol- 
igonucleotide. Unexpectedly, oligonucleotide Bm2 did 
compete for formation of complex B2. It is likely that 
complex B2 represents non-specific protein interaction 
with the probe. Oligonucleotide H also produced two 
additional complexes Hl and H2. Both represented spe- 
cific protein-DNA interactions since self-competition 
with oligonucleotide H was observed. Complex Hl was 
present in flC3 but not ccTC1 extracts. It exhibited 
competition with oligonucleotide P but not with B or 
Bm2. Complex H2 was present in both j?TC3 and olTC1 
extracts. Both complexes require further characteriza- 
tion. In theory either complex might represent binding 
of proteins at the enhancer core sequence within ol- 
igonucleotide H. 
The binding of aTC1 and jITC3 nuclear proteins to 
oligonucleotide B was further investigated over a range 
of salt concentrations. In this study two complexes were 
observed using the jITC3 extract (Fig. 3, arrows). The 
upper complex has a mobility similar to that of IUF-1. 
The lower complex has been described previously [28], 
and represents proteolytic breakdown of IUF-1. The 
IUF-1 complex was unaffected by salt over the range 
50-150 mM. In fact IUF-1 will bind to its TAAT box 
sequence at salt concentrations up to 500 mM (data not 
shown). Using the aTC1 extract no significant binding 
activity was observed at 50 mM salt. At 100 mM and 
150 mM salt two low mobility complexes appeared. 
Again these have been described previously and shown 
to represent binding of proteins at sites within oligonu- 
cleotide B that do not include the IUF-1 binding se- 
quence TCTAATG [28]. These results lend further sup- 
port to the conclusion that IUF-1 is expressed exclu- 
sively in the jITC3 cells but not in the aTC1 cells. 
Ohlsson et al. [lo] have reported that a factor, IPF-1, 
that is present in /ITC cells but absent from aTC cells 
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bound to an oligonucleotide (Pl) containing sequences 
from -85 to -64 of the rat insulin I gene [lo]. This 
sequence contains a TAAT box, and mutagenesis of the 
TAAT sequence to TCCT abolished the binding of IPF- 
1. To determine the relationship between IPF-1 and 
IUF- 1, competition experiments were performed using 
the human insulin gene probe P and the rat insulin I 
gene Pl and Plm2 oligonucleotides as competitors. The 
result showed that oligonucleotides P and Pl competed 
for formation of the IUF-1 complex, while oligonucleo- 
tide Plm2 failed to compete. Thus IUF-1 and IPF-1 
may be similar or closely related factors. 
The binding of clTC1 and DC3 nuclear proteins to 
oligonucleotide probes corresponding to the GGl and 
GG2 sites, the CRE, the NRE [17], and the SPl site at 
-346 to -341 was also studied. However, no substantial 
difference between the cell extracts was observed with 
any of these probes (data not shown). 
In conclusion, we have confirmed that the HLH 
heterodimer, IEF-1, that binds to the IEBl/NIR and 
IEBZ/FAR sequences in the rat insulin I gene and the 
IEBl/NIR sequence in the human insulin gene is pres- 
5OmM 
a P 
1OOmM 15OmM 
a B a P 
Fig. 3. Effect of KC1 on the binding of aTC1 and PC3 nuclear 
proteins to oligonucleotide B. Electrophoretic mobility shift assay 
using oligonucleotides B as probe and aTC1 and flC3 nuclear ex- 
tracts. Binding reactions were performed with the indicated final KC1 
concentration. The upper arrow points to the IUF-1 complex, while 
the lower arrow points to a complex form as result of proteolysis of 
IUF-1. 
Probe P 
Competitor - P Pl Plm2 
* ,* 
Fig. 4. Binding offlC3 nuclear proteins to oligonucleotide P. Electro- 
phoretic mobility shift assay using oligonucleotide P as probe and a 
/ITC3 nuclear extracts. The indicated unlabelled competitor oligonu- 
cleotides were used in approximately 50-fold excess. 
ent in both clTC1 and /?TC3 cells. The HLH factor USF 
that binds to the IEB2/FAR-equivalent sequence of the 
human insulin gene is also present in both cell types. 
This is in keeping with the widespread tissue distribu- 
tion of this factor [29]. The factor IUF-1 was shown to 
bind to three sites in the human insulin gene, the CTl, 
CT2 and CT3 boxes, and to be present inj3TC3 cells but 
absent from aTC1 cells. IUF-1 and the previously de- 
scribed factor IPF-1 [lo], are restricted to p cells and 
exhibit a similar binding specificity. They may represent 
similar factors, that exhibit the most tightly restricted 
tissue specificity of any insulin gene enhancer binding 
protein so far described. Interestingly, IUF-1 has also 
been shown to bind to an important regulatory se- 
quence in the /I cell-specific glucokinase promoter [30], 
indicating that it may play an important role in j? cell 
specific gene expression. Further investigation of this 
hypothesis and the potential role of IUF-1 in the glu- 
cose-mediated stimulation of insulin gene transcription 
[31] must await cloning of the cDNA for IUF-1. 
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